Abstract
(Abstracted from Obstet Gynecol Sci 2023;66:572–583 Polycystic ovary syndrome (PCOS) is frequently treated using low-dose hormonal pills with ethinylestradiol (EE) 35 μg combined with progestins for cycle control. Use of these combined oral contraceptives has been associated with metabolic syndrome, dyslipidemia, and a risk of cardiovascular events for women with metabolic disorders.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
